USD 0.68
(1.49%)
Year | Eps | Eps Growth |
---|---|---|
2023 | -13.32 USD | 79.68% |
2022 | -55.80 USD | -191.23% |
2021 | -19.16 USD | -253.65% |
2020 | 12.47 USD | 110.91% |
2019 | -114.29 USD | -4682.01% |
2018 | -2.39 USD | 77.11% |
2017 | -10.44 USD | 71.46% |
2016 | -36.58 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | -0.34 USD | 93.66% |
2024 Q2 | -1.35 USD | -297.06% |
2024 Q3 | -0.15 USD | 88.89% |
2023 Q4 | -5.36 USD | -624.32% |
2023 Q3 | -0.74 USD | -101.64% |
2023 FY | - USD | 79.68% |
2023 Q1 | -3.70 USD | 67.74% |
2023 Q2 | 45.00 USD | 1316.22% |
2022 Q2 | -3.28 USD | 77.58% |
2022 Q4 | -11.47 USD | 53.68% |
2022 FY | - USD | -191.23% |
2022 Q1 | -14.63 USD | -519.92% |
2022 Q3 | -24.76 USD | -654.88% |
2021 Q1 | -8.11 USD | -50.19% |
2021 Q2 | -9.93 USD | -22.44% |
2021 FY | - USD | -253.65% |
2021 Q4 | -2.36 USD | -293.44% |
2021 Q3 | 1.22 USD | 112.29% |
2020 Q2 | 13.05 USD | -28.41% |
2020 Q1 | 18.23 USD | -12.98% |
2020 FY | - USD | 110.91% |
2020 Q4 | -5.40 USD | 31.21% |
2020 Q3 | -7.85 USD | -160.15% |
2019 Q1 | -2.62 USD | 34.17% |
2019 FY | - USD | -4682.01% |
2019 Q4 | 20.95 USD | 146.71% |
2019 Q3 | -44.85 USD | 27.29% |
2019 Q2 | -61.68 USD | -2254.2% |
2018 Q1 | -6.34 USD | -188.18% |
2018 Q2 | 1.15 USD | 118.14% |
2018 Q3 | -13.27 USD | -1253.91% |
2018 Q4 | -3.98 USD | 70.01% |
2018 FY | - USD | 77.11% |
2017 FY | - USD | 71.46% |
2017 Q1 | -6.09 USD | 38.55% |
2017 Q2 | -5.33 USD | 12.48% |
2017 Q3 | -2.02 USD | 62.1% |
2017 Q4 | -2.20 USD | -8.91% |
2016 Q3 | -11.58 USD | 0.0% |
2016 Q4 | -9.91 USD | 14.42% |
2016 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
China Pharma Holdings, Inc. | -0.91 USD | -1363.736% |
cbdMD, Inc. | -13.32 USD | -0.0% |
Zomedica Corp. | -0.04 USD | -37740.909% |